Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of nadroparin on survival and disease progression in
patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer
or non-small-cell lung carcinoma (NSCLC).